An interventional study of Fractional CO₂ laser and Long-pulsed 1064-nm Nd:YAG laser in Skin Rejuvenation and Laser, sponsored by Universitas Padjadjaran. Recruiting at 1 site in Indonesia. Open to participants aged 30 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by Universitas Padjadjaran · Not applicable, Interventional, and Treatment
Skin rejuvenation is an effort to improve skin condition from the signs of skin aging. Skin aging is a complex biological process influenced by intrinsic and extrinsic factors, leading to changes in the epidermis and dermis, including decreased collagen characterized by dermal thinning, as well as alterations in skin appearance such as laxity and wrinkles. Laser therapy is one of the treatment modalities for skin rejuvenation, aiming to induce neocollagenesis and collagen remodeling, resulting in dermal thickening and improvement in skin appearance. Fractional CO₂ laser is an ablative laser considered the gold standard therapy for skin rejuvenation, whereas Long Pulsed (LP) Nd:YAG 1064 nm is a nonablative laser that is also used for skin rejuvenation. To date, there have been no studies evaluating the comparative effectiveness between fractional CO₂ laser and LP Nd:YAG 1064 nm for skin rejuvenation. Therefore, research comparing the effectiveness of fractional CO₂ laser and LP Nd:YAG 1064 nm for skin rejuvenation is needed, assessed based on dermal thickness, skin elasticity, wrinkles, and Global Aesthetic Improvement Scale scores.
Universitas Padjadjaran is the lead sponsor of 93 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In this split-face study, each participant received fractional CO₂ laser treatment on one side of the face. The treated side was randomly assigned. The procedure was performed three times at one-month intervals.
Procedure: Fractional CO₂ laser
In the same participants, the contralateral side of the face received long-pulsed 1064-nm Nd:YAG laser treatment. The side allocation was randomized. The procedure was performed three times at one-month intervals.
Procedure: Long-pulsed 1064-nm Nd:YAG laser
Fractional CO₂ laser was applied to one randomized side of the face in a split-face design for skin rejuvenation. Treatments were performed three times at one-month intervals. The laser delivers fractional ablative microthermal zones to stimulate dermal remodeling and collagen production. Treatment parameters were adjusted according to skin type and clinical indication.
Long-pulsed 1064-nm Nd:YAG laser was applied to the contralateral randomized side of the face in a split-face design for skin rejuvenation. Treatments were performed three times at one-month intervals. The laser delivers non-ablative dermal heating to stimulate collagen remodeling and improve skin texture and elasticity.
Dermal Thickness
Dermal thickness was assessed based on the two-dimensional area of the hyperechoic band that appears brighter than the epidermis on ultrasonography assessment.
Time frame: From enrollment to the end of treatment at 20 weeks
Skin Elasticity
Skin elasticity was defined as the ability of the skin to return to its original shape after deformation caused by mechanical traction. It was measured using a skin elasticity meter, and the R (recovery) value was assessed at 8 evaluation points on the face.
Time frame: From enrollment to the end of treatment at 20 weeks
Wrinkles
Lines or folds formed on the skin surface as a result of mechanical stress, skin dehydration, or repetitive muscular activity, and were evaluated using a facial skin analyzer
Time frame: From enrollment to the end of treatment at 20 weeks
Global Aesthetic Improvement Scale Scores
A 5-point rating scale (1-5) used to measure the degree of aesthetic improvement in patients following a procedure.
Time frame: From enrollment to the end of treatment at 20 weeks
Started Oct 2025 (actual). Primary completion is estimated for Mar 2026, 4 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitas Padjadjaran